Loading…

Gallic acid-based indanone derivatives as anticancer agents

Gallic acid-based indanone derivatives have been synthesised. Indanones 10, 11, 12 and 14 showed potent anticancer activity (IC 50 = 0.022–2.2 μM) against human cancer cell lines. The most active indanone against MCF-7, that is, hormone-dependent breast cancer cell line ( 10, IC 50 = 2.2 μM) showed...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2008-07, Vol.18 (14), p.3914-3918
Main Authors: Saxena, Hari Om, Faridi, Uzma, Srivastava, Suchita, Kumar, J.K., Darokar, M.P., Luqman, Suaib, Chanotiya, C.S., Krishna, Vinay, Negi, Arvind S., Khanuja, S.P.S.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gallic acid-based indanone derivatives have been synthesised. Indanones 10, 11, 12 and 14 showed potent anticancer activity (IC 50 = 0.022–2.2 μM) against human cancer cell lines. The most active indanone against MCF-7, that is, hormone-dependent breast cancer cell line ( 10, IC 50 = 2.2 μM) showed no toxicity to human erythrocytes even at higher concentrations (100 μg/ml, 258 μM). While, some of the indanones exhibited toxicity to erythrocytes at higher concentrations. Gallic acid-based indanones may further be optimised as better anticancer agents with low toxicity. Gallic acid-based indanone derivatives have been synthesised. Some of the indanones showed very good anticancer activity in MTT assay. Compounds 10, 11, 12 and 14 possessed potent anticancer activity against various human cancer cell lines. The most potent indanone ( 10, IC 50 = 2.2 μM), against MCF-7, that is, hormone-dependent breast cancer cell line, showed no toxicity to human erythrocytes even at higher concentrations (100 μg/ml, 258 μM). While, indanones 11, 12 and 14 showed toxicities to erythrocytes at higher concentrations.
ISSN:0960-894X
0968-0896
1464-3405
1464-3391
DOI:10.1016/j.bmcl.2008.06.039